Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species

Nephrology Dialysis Transplantation

Volumn 24, Issue 9, 2009, Pages 2637-2645

  Van Den Hoven, Mabel J ^a   Waanders, Femke ^b   Rops, Angelique L ^a   Kramer, Andrea B ^b   Van Goor, Harry ^b   Berden, Jo H ^a   Navis, Gerjan ^b   Van Der Vlag, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Glomerular basement membrane; Heparan sulfate; Heparanase; Proteinuria; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; DOXORUBICIN; HEPARAN SULFATE; HEPARANASE; LISINOPRIL; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME REGULATION; GLOMERULUS; IMMUNOFLUORESCENCE; KIDNEY DISEASE; MALE; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BASE SEQUENCE; CELL LINE; DNA PRIMERS; DOXORUBICIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONIDASE; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; PODOCYTES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; SPIRONOLACTONE;

EID: 69249158624     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp182     Document Type: Article

References (28)

1. Aldigier JC, Kanjanbuch T, Ma LJ et al. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005; 16: 3306-3314
2. Del Vecchio L, Procaccio M, Vigano S et al. Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol 2007; 3: 42-49
3. Waanders F, Rienstra H,Walther BoerMet al. Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats. Am J Physiol Renal Physiol 2009; 296: F1072-F1079
4. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123
5. Sato A, Saruta T. Aldosterone breakthrough during angiotensinconverting enzyme inhibitor therapy. Am J Hypertens 2003; 16: 781-788
6. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926
7. Raats CJ, Van Den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000; 57: 385-400
8. Van Den Hoven MJ, Rops AL, Vlodavsky I et al. Heparanase in glomerular diseases. Kidney Int 2007; 72: 543-548
9. Kramer A, Van Den Hoven M, Rops A et al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol 2006; 17: 2513-2520
10. Miyata K, Rahman M, Shokoji T et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906-2912
11. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 2007; 18: 2439-2446
12. Schupp N, Schmid U, Rutkowski P et al. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am J Physiol Renal Physiol 2007; 292: F1427-F1434
13. Van Den HovenMJ, Rops AL, BakkerMA et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006; 70: 2100-2108
14. Wijnhoven TJ, Van Den Hoven MJ, Ding H et al. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia 2008; 51: 372-382
15. Levidiotis V, Freeman C, Tikellis C et al. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol 2004; 15: 68-78
16. De Boer E, Navis G, Tiebosch AT et al. Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in adriamycin nephrotic rats. J Am Soc Nephrol 1999; 10: 2359-2366
17. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990; 186: 421-431
18. Durvasula RV, Petermann AT, Hiromura K et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65: 30-39
19. Rops AL, Van Den Hoven MJ, Baselmans MM et al. Heparan sulfate domains on cultured activated glomerular endothelial cells mediate leukocyte trafficking. Kidney Int 2008; 73: 52-62
20. Kramer AB, Van Der Meulen EF, Hamming I et al. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 2007; 71: 417-424
21. Shibata S, Nagase M, Yoshida S et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-364
22. Brinkkoetter PT, Holtgrefe S, Van Der Woude FJ et al. Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes. J Am Soc Nephrol 2004; 15: 33-40
23. Raats CJ, Bakker MA, Van Den Born J et al. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 1997; 272: 26734-26741
24. Van Den Hoven MJ, Wijnhoven TJ, Li JP et al. Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int 2008; 73: 278-287
25. Harvey SJ, Jarad G, Cunningham J et al. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. Am J Pathol 2007; 171: 139-152
26. Jeansson M, Haraldsson B. Glomerular size and charge selectivity in the mouse after exposure to glucosaminoglycan-degrading enzymes. J Am Soc Nephrol 2003; 14: 1756-1765
27. Wapstra FH, Navis GJ, van Goor H et al. ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy. Exp Nephrol 2001; 9: 21-27
28. Nakhoul F, Khankin E, Yaccob A et al. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. Am J Physiol Renal Physiol 2008; 294: F628-F637